Vicebio

Executive Summary

Vicebio is a UK-based preclinical biotechnology company developing next-generation vaccines for infectious diseases. Founded in 2016, the company leverages innovative antigen design and novel delivery systems to induce robust and durable immune responses against both established and emerging pathogens. With a focus on addressing unmet medical needs, Vicebio's platform aims to improve vaccine efficacy and accessibility. The company operates in a highly competitive landscape, but its differentiated approach could position it for partnerships or future clinical development. As a private entity with limited public information, Vicebio represents an early-stage investment opportunity in the infectious disease space. Currently, no financial or pipeline data are disclosed, and the company is likely in the research optimization phase. Given its preclinical status, significant milestones are required to validate its technology and progress toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead vaccine candidate40% success
• Q4 2026Partnership or licensing agreement with larger pharma30% success
• Q1 2027IND-enabling studies initiation20% success